Related Experiment Video
Updated: Jun 10, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Revisiting risankizumab: a newer biologic drug in dermatology
Aditya K Bubna1, Vinayak Viplav2
1Department of Dermatology, Katihar Medical College, Al-Karim University, Katihar, India - zimbabwa21@gmail.com.
Risankizumab, an interleukin 23p19 inhibitor, effectively treats plaque psoriasis and shows promise for other skin conditions like hidradenitis suppurativa, with a favorable safety profile.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Risankizumab is an FDA-approved interleukin 23p19 inhibitor for moderate to severe plaque psoriasis.
- Its efficacy extends beyond psoriasis to various other dermatologic conditions.
Purpose of the Study:
- To review the utility of risankizumab in psoriasis management.
- To explore the implications of risankizumab in off-label dermatologic disorders.
Main Methods:
- A comprehensive literature search was conducted across PubMed, Google Scholar, Scopus, and ResearchGate.
- Keywords included "Risankizumab," "Psoriasis," and "other dermatological disorders."
Main Results:
- Risankizumab demonstrates value in managing psoriasis and psoriatic arthropathy.
- Successful applications include hidradenitis suppurativa, pityriasis rubra pilaris, and pyoderma gangrenosum.
Conclusions:
- Risankizumab's therapeutic applications are broader than initially approved indications.
- The drug offers benefits for multiple dermatologic conditions with an acceptable safety profile.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:43Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...